Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
JA JAZZ Jazz Pharmaceuticals plc FY ended Apr 15, 2026 | $244.54 | $15.87B | $18.75B | $4.27B | $69.38M | -$356.15M | -41.87x | 3.72x | 58.20x |
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
AM AMRX Amneal Pharmaceuticals, Inc. FY ended Feb 13, 2026 | $17.54 | $5.60B | $8.43B | $3.02B | $504.78M | $72.06M | 79.73x | 1.86x | 16.40x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 31.63x | 3/3 | $11.35B | $67.66 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 3.04x | 3/3 | $4.48B | $26.72 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -8.82x | 3/3 | -$2.13B | — | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
JA JAZZ Jazz Pharmaceuticals plc FY ended Apr 15, 2026 | $244.54 | $15.87B | $18.75B | $4.27B | $69.38M | -$356.15M | -41.87x | 3.72x | 58.20x |
SU SUPN SUPERNUS PHARMACEUTICALS, INC. FY ended Feb 24, 2026 | $43.73 | $2.54B | $2.07B | $718.95M | $60.82M | -$38.55M | -64.31x | 3.54x | 29.22x |
AM AMRX Amneal Pharmaceuticals, Inc. FY ended Feb 13, 2026 | $17.54 | $5.60B | $8.43B | $3.02B | $504.78M | $72.06M | 79.73x | 1.86x | 16.40x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 31.63x | 3/3 | $11.35B | $67.66 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 3.04x | 3/3 | $4.48B | $26.72 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -8.82x | 3/3 | -$2.13B | — | Peer averages are not economically meaningful for this method. |